Press

WORLDWIDE TISSUE ENGINEERING AND REGENERATIVE MEDICINE MARKET FORECAST TO GROW 16% ANNUALLY THROUGH 2013

HUNTINGTON BEACH, Calif.-March 4, 2009--(BUSINESS WIRE)--According to a new report, Worldwide Markets and Emerging Technologies for Tissue Engineering and Regenerative Medicine, distributed exclusively by Life Science Intelligence (LSI), the largely untapped global market potential for tissue engineering and regenerative medicine products will exceed $118 billion by 2013.  The actual current market, which represents only a fraction of the potential market, is estimated at $1.5 billion in 2008.  The report forecasts rapid growth driven by various factors, including increased adoption in various clinical areas and trends in international markets.

Substantial growth is expected in multiple product segments.  Target procedure areas with high volume and/or high growth potential include neurologic, orthopaedic, organ regeneration, cardiovascular, urologic, and wound care.  In addition to high potential in various clinical procedure areas, major opportunities exist in international markets as a whole.  The U.S, which accounted for 90% of the global market in 2008, will remain the largest and enjoy rapid growth.  However, over the forecast period covered in this study, the markets in Europe, Japan, and Rest of World are forecast to grow at significantly higher rates compared to the U.S.

Over 220 companies are covered in this in-depth competitive intelligence report including:  Aastrom Biosciences, Advanced BioHealing, Advanced Cell Technology, Aldagen, Arteriocyte, Athersys, Biofisica, Bioheart, BioMimetic Therapeutics, Cardium Therapeutics, Cerapedics, Cook Biotech, C.R. Bard, CrossCart, CryoLife, Cytograft Tissue Engineering, Cytori Therapeutics, Gamida Cell, GeneGrafts, GenVec, Genzyme, Geron, Integra LifeSciences, International Stem Cell, Isolagen, Johnson & Johnson, LifeCell/Kinetic Concepts, Medtronic, Mesoblast, MicroIslet, Neuralstem, Novartis, Novocell, Organogenesis, Orthopeutics, Osiris Therapeutics, Pfizer, Pluristem Therapeutics, ReGen Biologics, ReNeuron, Scil Technology, StemCells, StemCor Systems, Stryker, Tengion, and Tepha, among others.

Immediate access to the Table of Contents for this report is available at:  lifescienceintelligence.com/market-reports-page.php?id=INT-WW091BT.

About Life Science Intelligence (LSI)®
LSI delivers high-quality market data and information to medical technology executives, entrepreneurs, and investors.  LSI produces the EMT (Emerging Medical Technologies)® Database, medtech market reports, and provides global custom research services, including market assessments and physician surveys.  www.LSintelligence.com.

Contact:
Life Science Intelligence
Scott Pantel, 1 714 847 3540
scott@LSintelligence.com